Shanghai Pharmaceuticals' product gross profit margin 2022
In 2022, Shanghai Pharmaceutical Group Co., Ltd. generated an operating revenue of more than 26 billion yuan from its pharmaceutical products. The products for anti-tumor and immunomodulator purposes recorded the highest gross profit margin of almost 81 percent. The enterprise is one of the largest national pharmaceutical groups in China which owns over 1,700 pharmacies.